JUNE 22-23, 2021 | VIRTUAL EVENT
AGENDA – ALL TIMES ARE IN EASTERN TIME
Marni Edelhart, VP, Content, Momentum Events
Ben Greenzweig, CEO, Momentum Events
As psychedelics continue to move from the fringes to increasingly popular acceptance, government officials are beginning to put their influence behind Them. This session offers a first hand perspective from an elected official about putting forth a pro-psychedelic and empathogen bill.

Including:
  • How state mandates and support can drive progress
  • The role of state-sponsored research in drug policy reform
  • The need to differentiate clinical vs recreational use
Alex Dominguez, State Representative, State of Texas
Popular agreement suggests that the legal future of psychedelics will take place in the clinical as opposed to the recreational realm. Therefore, clinical trials and research will be very key to expanding access and understanding how these treatments actually affect our brains.

  • What have we learned from the latest clinical trials
  • Who is funding the research
  • Where are the gaps in understanding that need more study
Nolan Williams MD, Assistant Professor of Psychiatry & Behavioral Science, Stanford University
Ronan Levy, Executive Chairman, Field Trip Health Ltd.
Owen Muir MD, Chief Innovation Officer, Brooklyn Minds
One thing that most psychedelic enthusiasts and researchers can agree on is that anyone experimenting with or being treated with psychedelics or empathogens need support to do so safely and effectively. This session will examine the potential for a community-driven approach to psychedelics that ensures:
  • More access to support and information about psychedelics
  • A strong base of advocates for psychedelic access
  • Increased educational resources about psychedelics
Mackenzie Bullard, Project Management Specialist, Boston Medical Center
Ifetayo Harvey, Founder, People of Color Psychedelic Collective
The path forward for Psychedelics will not mirror that of Cannabis, but one similarity is the extreme growth the industry is seeing that at some point will face a dip. Some of that dip will come in the form of mergers and acquisitions.

This session will address:
  • The potential for a “bubble” in Psychedelic Start-Ups
  • What CBD and Cannabis can teach us about risks to growth
  • Where Will Long Term Success Be Found for Psychedelics
Benton Bodamer, Member, Dickinson Wright
The dramatic results offered by psychedelic treatments can have the adverse effect that care ends after a single therapeutic interaction. Even though patients may feel relief from their trauma or mental illness, however, they often still need support to move forward.

This panel will cover:
  • Post-treatment support strategies
  • Warning signs for clients who may experience post-treatment stress
  • Collaborative approaches for building a more supportive approach to psychedelics
Joe Moore, Co-Founder, Psychedelics Today
Marni Edelhart, VP, Content, Momentum Events
Lynn Marie Morski, M.D., JD, President, Psychedelic Medicine Association
In 2020, Oregon became the first state in the nation to create a Psilocybin therapy program. However, the passage of Measure 109 was only the first step. Sam Chapman was the Campaign Manager for Measure 109 and is now guiding the development of rules and regulations over the next two years to create the most affordable, accessible, equitable program possible.

This session will provide:
  • A brief overview of what Measure 109 does and does not do
  • Applicable lessons learned for states considering the psychedelic therapy model
  • An overview of what the next two years of rulemaking in Oregon will entail
Sam Chapman, Executive Director, The Healing Advocacy Fund
Michael Pollan’s popular book about psychedelics and empathogens is titled “How to Change Your Mind” because these treatments have the potential power to truly change the ways in which we think and how our brains work. Therefore, perhaps we could look at implementing them not only to treat trauma, but to help prevent it by treating the hurtful impulses that cause it.

This session will cover:
  • Psychedelics and the treatment of layered, complex trauma
  • The potential of Psychedelics to shift a racist mindset
  • Business models that create more inclusive access
Nicole Buchanan, Professor of Psychology, Michigan State University
Investment in psychedelics and empathogens has increased so much that many funds are actually focused solely on this industry. Therefore, both investors and start-ups need to be especially critical about where they are investing and/or seeking their funds.

During this session:
  • Hear from active investors about how they evaluate potential investments
  • Tap into a risk profile view of investments in this space
  • Learn how to make your start-up stand out when pitching investors
Moderator:
Amanda Eilian, Co-Founder, Able Partners

Holly Jacobus, Investment Partner, Joyance & Social Starts
Stephen Hays, Founder, What If Ventures
Sonia Weiss, General Partner, WPSS Investments
In recent years there has been increasing interest in use of psilocybin for relief of a variety of challenging mental health conditions, including anxiety and depression at the end of life.

This session will address:
  • An innovative effort to remove barriers to access to psilocybin therapy for seriously ill patients under Right to Try laws
  • Oregon’s Pioneering Psilocybin Services Act
  • Opening Access via Right to Try
Kathryn Tucker, Special Counsel and Co-Chair Psychedelics Practice, Emerge Law Group; Founding Member, Psychedelic Bar Association
Berra Yazar-Kolinski, Deputy Director and Head of Research Development, MAPS
Daniel Carcillo, Former NHL player, Founder, Wesana Health
Perhaps no single signal better reflects the rising acceptance of psychedelic treatments than the buy-in of large, established pharmaceutical companies.

This session covers:
  • How mainstream pharma companies are investing in Psychedelics
  • Why this rising tide will lift most boats
  • Ways that the psychedelic community can engage with Big Pharma to grow together
The growth of psychedelics stems from a growing understanding that we have only just begun to into brain health and how to improve it. This session will use Psychedelics as a jumping off point for a broader look at trends shaping the future of brain health.

Moderator:
Ben Greenzweig, CEO, Momentum Events

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close